Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Adjusted Mean Change From Baseline in FPG

To compare the change from baseline in fasting plasma glucose (FPG) to week 24 (LOCF) between dapagliflozin and placebo

Time frame: Baseline to week 24

Adjusted Mean Change From Baseline in Total Body Weight

To compare the change from baseline in total body weight to week 24 (LOCF) between dapagliflozin and placebo

Time frame: Baseline to week 24

Proportion of Participants With HbA1c Value < 7.0% at Week 24 (LOCF)

To compare the proportion of subjects achieving a therapeutic glycemic response, defined as HbA1c \<7.0%, at week 24 (LOCF) between dapagliflozin and placebo

Time frame: Baseline to week 24

Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure

To compare the change from baseline in seated systolic blood pressure (SBP) to week 8 (LOCF) between dapagliflozin and placebo

Time frame: Baseline to week 8